NCT07101055View on ClinicalTrials.gov

Pharmacokinetics of Oral Letermovir in Adults With End-Stage Kidney Disease With or Without Haemodialysis

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

December 31, 2027

Conditions
End-Stage Kidney Disease (ESKD)
Interventions
DRUG

Letermovir 480 mg [PREVYMIS]

A single 480 mg oral dose of letermovir (2 x 240 mg tablets).

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Royal Brisbane and Women's Hospital

OTHER_GOV

lead

Jason A Roberts

OTHER